NCT02721732 2026-01-29Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are MetastaticM.D. Anderson Cancer CenterPhase 2 Active not recruiting157 enrolled 26 charts
NCT03910660 2025-10-20A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.BioXcel Therapeutics IncPhase 1/2 Completed98 enrolled